Partnership to test SARS-CoV2 DNA vaccine in healthy Australians.
The University of Sydney is testing a novel DNA-based COVID-19 vaccine with the goal of being administered using a needle-free system.
The University of Sydney is announcing the commencement of an extended Phase 1 Human Trial in Australia, evaluating a COVID-19 gene-based vaccine developed by BioNet and Technovalia and delivered via a needle-free system.
Under a $3million grant from the Australian Medical Research Future Fund (MRFF) Coronavirus Research Response, Associate Professor Nicholas Wood from the University of Sydney, Australia and will lead a team to evaluate the vaccine candidate for the first time in humans.